Oncoinvent ASA

As of June 30, 2025, Oncoinvent ASA carries a market capitalization of 53.00M, placing it among publicly traded companies globally. Its enterprise value stands at -12.91M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2025, Oncoinvent ASA has 609,941.00 shares outstanding.

These figures are as of June 30, 2025.

As of June 30, 2025, Oncoinvent ASA maintains a current ratio of 4.39, meaning it holds 4.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2025.

As of the close on October 20, 2026, Oncoinvent ASA's stock has declined approximately 7.54% over the past 52 weeks. The 50-day moving average sits at 79.93, while the 200-day moving average is 66.64.

As of June 30, 2025, Oncoinvent ASA holds 65.92M in cash and equivalents against - - in total debt, resulting in a net debt position of -65.92M. Total book value stands at 67.00M, with working capital of 66.93M providing operational flexibility.

Oncoinvent ASA's most recent stock split took place on January 22, 2026 with a 100:1 split ratio.